|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
| Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
| Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, |
|
 |
| |
| |
| Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
|
| Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
|
| Affiliations(s): "1
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
2
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
3
Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea
4
Kansai Electric Power Medical Research Institute, Kobe, Japan
5
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
6
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
7
Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
8
Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan
9
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan
10
Department of Cardiovascular Medicine, Saga University, Saga, Japan
11
Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan
12
Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan
13
Boehringer Ingelheim Korea Ltd, Seoul, Korea
14
IQVIA, Espoo, Finland
15
Boehringer Ingelheim International GmbH, Ingelheim, Germany
16
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
17
Kansai Electric Power Hospital, Osaka, Japan
" |
Publication(s): "JDI journal
Virtual Conference: ACC, May 2021"
|
| Document Type(s): Article, |
| Countries: Japan, Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis, |
|
|
| |
| |
| Hypercholesterolaemia control in Spain: The same situation with different regional realities
|
| Author(s): Juan Pedro-Botet, Núria Plana, José María Mostaza, Juan José Gómez-Doblas, María Rosa Fernández Olmo, Carlos Escobar Cervantes, José Luis Díaz-Díaz, Raquel Campuzano Ruiz, Pedro Valdivielso, Juan Cosín-Sales
|
| Affiliations(s): Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España
|
Publication(s): Clinica e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Espanola de Arteriosclerosis, S0214-9168(23)00027-X. 27 Apr. 2023, doi:10.1016/j.arteri.2023.04.001
|
| Document Type(s): Abstract, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2023 |
|
L:
A: |
Spanish
Clinical setting: Primary care, Public Health, Quality of life, Survey research, |
|
|
| |
| |
| Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan |
| Author(s): Masanobu Ishii, Takashi Kawai, Kenichi Tsujita, Ataru Igarashi, Manabu Suzuki, Hisato Deguchi, Jovelle Fernandez |
| Affiliations(s): Masanobu Ishii
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University [Japan]
Takashi Kawai
Department of Gastroenterological Endoscopy, Tokyo Medical University [Japan]
Kenichi Tsujita
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University [Japan]
Ataru Igarashi
Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo [Japan]
Manabu Suzuki
Japan Medical Office, Takeda Pharmaceutical Company Limited [Japan]
Hisato Deguchi
Japan Medical Office, Takeda Pharmaceutical Company Limited [Japan]
Jovelle Fernandez
Japan Medical Office, Takeda Pharmaceutical Company Limited [Japan] |
Publication(s): Circulation Journal
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2022 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension |
| Author(s): Allan Lawrie1,2|Neil Hamilton3|Steven Wood2,4|Fernando Exposto5|Ruvimbo Muzwidzwa5|Louise Raiteri5|Amélie Beaudet6|Audrey Muller6|Rafael Sauter6|Nadia Pillai6|David G. Kiel |
| Affiliations(s): 1National Heart and Lung Institute,Imperial College London, London, UK2Insigneo Institute for In?Silico Medicine,University of Sheffield, Sheffield, UK3Sheffield Pulmonary Vascular DiseaseUnit, Sheffield Teaching Hospitals NHSFoundation Trust, Royal HallamshireHospital, Sheffield, UK4Scientific Computing, Sheffield TeachingHospitals NHS Foundation Trust, RoyalHallamshire Hospital, Sheffield, UK5IQVIA, London, UK6Actelion Pharmaceuticals Ltd.,Allschwil, Switzerland7Department of Infection, Immunity andCardiovascular Disease, University ofSheffield, Sheffield, UK |
Publication(s): Pulmonary Circulation. 2022;12:e12136.wileyonlinelibrary.com/journal/pul2|1of10https://doi.org/10.1002/pul2.12136
|
| Document Type(s): Article, |
| Countries: Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Respiratory disease,
2022 |
|
L:
A: |
English
Observational study, Retrospective cohort analysis, |
|
|
| |
| |
| Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal |
| Author(s): Nuno Marques 1, Laetitia Gerlier 2, Mafalda Ramos 3, Helder Pereira 4, Sérgia Rocha 5, Ana Catarina Fonseca 6, Ana André 7, Ricardo Melo 8, Eduard Sidelnikov 9 |
| Affiliations(s): 1Department of Cardiology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal.
2IQVIA, Zaventem, Belgium.
3IQVIA, Zaventem, Belgium. Electronic address: mafalda.ramos@iqvia.com.
4Department of Cardiology, Hospital Garcia de Orta, Almada, Portugal.
5Department of Cardiology, Hospital de Braga, Braga, Portugal.
6Department of Neurology, Hospital de Santa Maria, Universidade de Lisboa, Lisboa, Portugal.
7Department of Neurology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal.
8Amgen SA, Portugal.
9Amgen (Europe) GmbH, Rotkreuz, Switzerland. |
Publication(s): PMID: 33581948 DOI: 10.1016/j.repc.2020.05.019
IQVIA HEOR Zaventem Brussels
Revista Portuguesa de Cardiologia Volume 40, Issue 2, February 2021, Pages 109-115.
|
| Document Type(s): Article, |
| Countries: Portugal, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Health economics,
2021 |
|
L:
A: |
English
Burden of illness, Clinical setting: Primary care, Prospective study, |
|
|
| |
| |
| Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE |
| Author(s): P. Escribano (1), S. Gaine (2), P. Biedermann (3), A. Muller (3), M. Valge (4), T. Lange (5), S. Söderberg (6) |
| Affiliations(s): 1 Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 de Octubre, Madrid, Spain
2 National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland
3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
4 StatFinn Estonia OÜ, Tartu, Estonia (now IQVIA)
5 University Medical Center Regensburg, Regensburg, Germany
6 Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, Sweden |
Publication(s): JO - The Journal of Heart and Lung Transplantation
VL - 40
IS - 4, Supplement
SP - S109
PY - 2021
DA - 2021/04/01/
SN - 1053-2498
|
| Document Type(s): Abstract, |
| Countries: Canada, Europe, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2021 |
|
L:
A: |
English
Epidemiological study, Observational study, |
|
|
| |
| |
| Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from
the empagliflozin comparative effectiveness and safety (EMPRISE) study
|
| Author(s): A. Karasik1
, S. Lanzinger2
, E. Chia-Hui Tan3
, D. Yabe4
, D. Jung Kim5
, W. H-H Sheu6
, C. MelzerCohen1
, R.W. Holl2
, K. Ha5
, T. Nyström7
, L. Niskanen8
, M. Linnemann Jensen9
, M.H. Kyaw10, J.
Núñez11, EMPRISE EU and East Asia Study Group; |
| Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2
Inst. for
Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese
Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of
Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine,
Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical
Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine,
Päijät-Häme Central Hospital, Lahti, Finland, 9
IQVIA, Copenhagen, Denmark, 10Boehringer
Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico
Universitario de Valencia, Valencia, Spain |
Publication(s):
https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Population Based Study, |
|
|
| |
| |
| Cardiovascular Effectiveness of Empagliflozin Compared to DPP-4i in Routine Care in East Asia: Results from the EMPRISE study |
| Author(s): Dae Jung Kim, Wayne H.-H. Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Elise Chia-Hui Tan, Yusuke Taneda, Vanessa Lei, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Group, Boehringer Ingelheim International GmbH, Ingelheim, Germany, StatFinn - EPID Research an IQVIA Company, Espoo, Finland |
| Affiliations(s): 1 Ajou University, Suwon, South Korea; 2 Taichung Veterans General Hospital, Taichung, Taiwan; 3 Gachon University Gil Medical Center, Incheon, South Korea; 4 Kansai Electric Power Medical Research Institute, Kobe, Japan; 5 Gifu University Graduate School of Medicine, Gifu, Japan; 6 National Research Institute of Chinese Medicine, Taipei, Taiwan; 7 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 8 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 9 IQVIA, Espoo, Finland; 10 Boehringer Ingelheim International GmbH, Ingelheim, Germany; 11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12 Kansai Electric Power Hospital, Osaka, Japan |
Publication(s): J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 542.
https://doi.org/10.1016/S0735-1097(21)01901-X
|
| Document Type(s): Abstract, Presentation, |
| Countries: Japan, South Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Observational study, |
|
|
| |
| |
| Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results |
| Author(s): T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen |
| Affiliations(s): Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland; |
Publication(s): European Journal of Heart Failure (2021)23(Suppl. S2) 2?322doi:10.1002/ejhf.2297
|
| Document Type(s): Abstract, Article, |
| Countries: Finland, Germany, Israel, Spain, Sweden, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Meta analysis, Methodology, Population Based Study, |
|
|
| |
| |
 1 of 53 
|
|
